Triple-Negative Breast Cancer (TNBC) Cell Metastasis is Controlled by the Opposing Actions of 5alpha-dihydroprogesterone (5alphap) and 3alpha-dihydroprogesterone (3alphahp) on Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases

doi:10.21203/rs.3.rs-76129/v1

Download PDF

Research article

Triple-Negative Breast Cancer (TNBC) Cell Metastasis is Controlled by the Opposing Actions of 5alpha-dihydroprogesterone (5alphap) and 3alpha-dihydroprogesterone (3alphahp) on Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases

https://doi.org/10.21203/rs.3.rs-76129/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

Triple receptor-negative breast cancers (TNBC) comprise up to 20% of all breast cancers and are the most aggressive mammary cancer subtype, marked by early-onset metastasis, high tumor recurrence rate, and low overall survival. Because TNBC cells lack expression of the estrogen receptor (ER), progesterone receptor (PR) and excess human epidermal growth factor receptor 2 (HER2), there have been no hormone-based explanations and therapeutics for TNBC. Our previous studies had shown that the endogenously produced hormones, 5αdihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP), respectively, stimulate and inhibit TNBC cell proliferation and primary tumor development. Here we examined the role of 5αP and 3αHP in controlling metastasis of TNBC (MDA-MB-231)human breast cells. The objectives were to determine the effects of 5αP and 3αHP on TNBC cell (a) adhesion, migration and invasion and (b) expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).

Methods

MDA-MB-231 human breast cells were incubated in medium without (control) or with 5αP or 3αHP. Effects on adhesion were examined by previously validated detachment assays. Effects on migration and invasion were measured by transwell assays employing modified Boyden chambers. Effects on expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 were determined by reverse transcription polymerase chain reaction (RT-PCR).

Results

5αP stimulated, whereas 3αHP suppressed, TNBC cell detachment, migration and invasion. 5αP stimulated expression of MMP-2 and MMP-9, and inhibited expression of TIMP-1 and TIMP-2, whereas 3αHP inhibited expression of MMPs and stimulated expression of TIMPS.

Conclusions

Here we show for the first time that 5αP stimulates and 3αHP suppresses the key elements of metastasis (adhesion, migration, invasion) in TNBC cells, and that these opposing actions correlate with the opposing effects of these two hormones on MMP and TIMP expression. The results indicate that the relative concentrations of the cancer-promoter hormone (5αP) and the cancer-suppressor hormone (3αHP) in the breast microenvironment control TNBC cell metastasis, and suggest that blocking 5αP synthesis and increasing 3αHP concentrations in the breast microenvironment could provide the first hormone-based therapeutic regimen to arrest TNBC progression and metastasis.

Cancer Biology

triple-negative breast cancers

TNBC

metastasis

hormonal control

cell adhesion

migration

invasion

breast cancer-promoter hormone

5-alpha-dihydroprogesterone (5alpha-P)

3-alpha-dihydroprogesterone

(3alpha-HP)

TNBC-suppressor hormone

TNBC-promoter hormone

Breast cancer is the most frequently diagnosed cancer in women [1] and triple-negative breast cancer (TNBC), the subtype which tests negative for expression of the estrogen receptor (ER), progesterone receptor (PR) and excess human epidermal growth factor receptor 2 (HER2) [(2] comprises up to 20% of all breast cancers [2,3]. TNBC is the most aggressive mammary cancer subtype, marked by early-onset metastasis, high tumor recurrence rate, and low overall survival [4,5,6]. The etiology of TNBC is not understood and the lack of receptor expression means that the current hormone-based targeted therapies which are applicable for receptor-positive breast cancers are ineffective, and the only proven method for systemic management of TNBC is chemotherapy [7,8], which provides only limited survival for the patients, along with considerable untoward side-effects. There is, therefore, an urgent need to understand the cause(s) and regulation of TNBC , in particular the progression to metastasis, which is the leading cause of death from all breast cancers.

Previous studies demonstrated that breast tissues [9] and human breast cell lines[ 10] readily convert progesterone to 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP) by the actions, respectively, of 5α-reductase and 3α-HSO (Figure 1) and that tumors and tumorigenic breast cell lines produce more 5aP and less 3aHP than normal (non-tumorous) breast tissue and non-tumorigenic breast cell lines, due to up-regulation of 5α-reductase expression and down-regulation of 3α-HSO expression [ 9-12]. Particularly noteworthy with respect to the present studies are the prominent differences in expression between adjacent triple receptor-negative normal and tumor breast tissues [11].

In vitro studies with various breast cell lines, including MDA-MB-231 cells ( which have been characterized as human TNBC cells [13]), showed that 5aP acts as a breast cancer-promoter hormone by stimulating cell proliferation and inhibiting apoptosis and adhesion, whereas 3αHP acts as a cancer-suppressor hormone by having the opposite effects [9,14]. The pro-cancer and anti-cancer actions, respectively, of 5αP and 3αHP were confirmed with in vivo xenograft studies [15] in which MDA-MB-231 cells were implanted in mammary fat pads of immunosuppressed mice treated with 5αP and/or 3αHP. The results showed that 5αP stimulated, whereas 3αHP inhibited, initiation and subsequent growth of primary human TNBC cell tumors; in addition, 3αHP resulted in regression of tumors that were already established.

Having demonstrated that TNBC cell proliferation and the onset and growth of primary TNBC tumors are controlled by the relative concentrations of 5αP and 3αHP in the microenvironment, it was of interest to determine the effects of 5αP and 3αHP on metastasis, the process that involves the escape of activated tumor cells from the neoplasm followed by migration to, and invasion of, distant locations where they form the malignant growths which are the primary cause of cancer deaths [16]. The metastatic cascade depends on changes in adhesion properties between cells and between cells and the extracellular matrix (ECM)[17], and the changes in adhesion involve recruitment of proteases to degrade the ECM, basement membrane and cell junctions. The matrix metalloproteinases (MMPs) are the main proteases involved in remodelling the ECM [18,19] and thus have a direct role in potentiating migration and invasion of metastatic cells [19,20]. The MMPs are secreted in a latent form, bound to specific inhibitors called the tissue inhibitors of metalloproteinases (TIMPs) [21]. Activation of MMPs results when the TIMPs are proteolytically cleaved from them. Since the TIMPs inhibit the enzymatic activity of the MMPs, the balance between the level of active MMPs and available TIMPs is a pivotal determinant of ECM turnover [22]. Consequently, factors that result in changes in expression levels of MMPs and/or TIMPs can affect adhesive, migratory and invasive properties [ 23,24] and correlate with breast cancer prognostic factors [25].

The objectives of the current studies were to determine the effects of 5αP and 3αHP on triple-negative (MDA-MB-231) breast cells in terms of (a) adhesion, migration and invasion and (b) expression of MMP-2, MMP-9, TIMP-1 and TIMP-2.Here we show for the first time that 5αP stimulates, whereas 3αHP inhibits, receptor-negative breast cell detachment, migration and invasion , and that these opposing actions are via opposing effects of these two hormones on MMP and TIMP expression. The results provide further evidence that the hormones, 5αP and 3αHP, play important roles in stimulating or suppressing various stages leading to deregulation from the normal state to onset and growth of primary tumors and to development of metastatic lesions of TNBC. The results also indicate that therapeutics based on raising the 3αHP:5αP concentration ratio in the microenvironment have the potential to suppress TNBC progression and metastasis.

Chemicals

The steroid hormones, 3αHP and 5αP, were obtained from Steraloids Inc (Wilton, N.H., USA). Cell culture media, insulin, penicillin and streptomycin were obtained from Sigma Chemical Co. (Oakville, ON). Calf serum was purchased from Invitrogen (Burlington, ON). Other chemicals were of analytical grade and purchased from Sigma Chemical Co., BDH Inc., (Toronto, ON) VWR (Mississauga, ON) or Fisher Scientific Ltd., (Toronto, ON). Ethanol was double glass distilled.

Cell Culture

The human breast cell line, MDA-MB-231, was obtained from the American Type Culture Collection (Rockville, MD). The cells were grown in a 1:1 Ham's F12 Medium and Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM glutamine, 100 units/ml penicillin, 78 units/ml streptomycin, 1.2 mg/ml sodium bicarbonate and 10% full calf serum as previously described [14]. Cells were grown in T-75 flasks (Sarstedt) in a humidified incubator at 37°C and a 5% CO₂ atmosphere, and were harvested at approximately 80% confluence using 0.025% trypsin and EDTA (0.2 M) in phosphate-buffered saline (PBS) solution (pH 7.3).

Cell adhesion. Cell adhesion was determined by a detachment assay described previously [9]

Cell Migration and Invasion Assays

Cell migration and invasion transwell assays were carried out in modified Boyden chambers [26,27] using 24-well cell culture plates with inserts containing 8 μm pore polycarbonate membranes (BD Biosciences, Canaan, CT). The treatment media contained dextran-coated charcoal-treated (DCC-treated) calf serum at 2% for 5αP studies, and 5% for 3αHP studies along with double distilled ethanol at a final concentration of 0.1% without (control) or with either 5αP (10^-6M) or 3αHP (10^-6M), respectively. The reason for using higher (5%) serum concentrations for the 3αHP studies, was to have higher numbers of migrating/invading cells in the controls, thereby facilitating better detection of the suppressive effects of 3αHP.

(a) Migration. Migration was defined as the ability of cells to move through the 8 μm pores. Cells were seeded at 1x10⁵/200 μl of treatment medium in each of the upper chambers and 800 μl of the respective treatment medium was added to the bottom wells. After incubation of the plates for 6 hours (37C; 5% CO₂), non-migrated cells were gently removed from the top of the filter using cotton swabs. The bottom of each filter was gently rinsed with Earl’s Balanced Salt Solution (BSS) and the cells that had migrated to the lower surface of the polycarbonate membrane were fixed in 2% formaldehyde and stained with Giemsa stain. The filters were detached from the bottom of the inserts, mounted on glass slides, and viewed microscopically. The number of migrated cells per well was determined by counting the cells within a standardized grid of 16 equal-sized fields, which together covered about 90% of the membrane surface. Each treatment consisted of 4 or 5 replicate wells and experiments were repeated at least three times.

(b) Invasion.Invasion was defined as the ability of cells to penetrate the 8 μm pores of polycarbonate membranes coated with 2.5 mg/mL of matrigel (BD Biosciences, Canaan, CT), a reconstituted basement membrane extract of the Englebreth-Holm-Swarm mouse sarcoma [28]. The gel was allowed to polymerize for 1h at room temperature. Then 1x10⁵cells in 200 μl of respective treatment medium were seeded in the upper chambers and 800 μl of the same treatment medium was added to the bottom wells. Incubation was for 24 hours at 37°C, and cells having invaded the bottom of the polycarbonate membrane were scored as described above for migration. Each treatment consisted of 4 or 5 replicate wells and experiments were repeated at least three times.

MMP and TIMP expression studies

Cells were seeded in 35 mm culture dishes (Falcon) at 5x10⁴ cells per dish in the respective control/treatment media and allowed to attach for 24 hours. They were then incubated for 48 hours in medium containing serum at 5% for the 3αHP studies and 2% for the 5αP studies. After 48 hours cells were harvested and RNA was isolated.

RNA Isolation & Reverse Transcription. RNA was extracted from the cells using RNeasy Mini kit (Qiagen) following the manufacturer’s protocol. Complimentary DNA (cDNA) was obtained from 10 µl of RNA using Oligo(dT) (Invitrogen), SuperScript II Reverse Transcriptase (Invitrogen) in a total volume of 20 µl following the manufacturers protocol.

RT-PCR and Quantification. RT-PCR was performed on a GeneAmp PCR System 9600 (Perkin Elmer) in triplicate. PCR primers were purchased from Invitrogen with the sequences given in Table 1. PCR conditions were as follows: 95°C denaturing for 2 minutes followed by 30 seconds of annealing at 42°C followed by extension for 1 minute and 30 seconds at 72°C. For each reaction, a 1 µl aliquot of cDNA product was amplified in a 50 µl total volume using 1 U of Platinum Taq DNA Polymerase (Invitrogen), 50 mM MgCl₂, 10 mM dNTP’s, and 4 µl of each primer. The same cycling conditions and PCR reagent concentrations were used for each set of primers. PCR products were confirmed by separation on a 1.5% agarose gel and quantification using the Quantity One (BioRad) program.

Statistics

Results are given as mean ± SEM. Data were analyzed by unpaired Student’s t-test with InStat software (GraphPad, San Diego, CA). Differences were considered significant if p < 0.05.

Table 1. PCR primers (upstream; downstream) used in the MMP and TIMP expression studies.

Effects of 5αP and 3αHP on proliferation and cell adhesion.

Proliferation studies (Figure 2A) showed that 5αP dose-dependently stimulated, and 3αHP inhibited, [³H]thymidine incorporation, confirming that the MDA-MB-231 cells used for this study were responsive to 5aP and 3αHP as previously reported [14]. The effects of 5αP and 3αHP on adhesion were determined by detachment assays (Figure 2B) which showed that detachment is dose-dependently increased by 5αP, and decreased by 3αHP.

Effects of 5αP and 3αHP on cell migration and invasion

Figure 3 shows representative microscopic fields of undersides of Boyden chamber membranes from control (Figure 3Ai) and 5αP-treated (Figure 3Aii) MDA-MB-231 cells, indicating the 8μm membrane pores and cells that have migrated through the pores and attached to, and spread on, the underside, which were scored as 'migrated'. 5αP resulted in significant increases (Figure 3B), whereas 3αHP resulted in significant decreases (Figure 3C), in number of migrated cells. Similarly, 5αP increased, whereas 3αHP decreased, the invasive activities of the cells (Figures 3D & 3E).

Effects of 5αP and 3αHP on expression of MMPs and gelatinase activity.

Since MMPs are the main proteases involved in remodelling the ECM and thus have a direct role in migration and invasion, we examined the effects of 5αP and 3αHP on expression levels of MMP-2 and MMP-9.

The results showed that 5αP increased expression of MMP-2 and MMP-9 (Figures 4A & 4C), whereas 3αHP decreased expression of MMP-2 and MMP-9 (Figures 4B & 4D). As a measure of the active proteolytic MMP levels, gelatinase expression was determined; 5αP resulted in stimulation (Figure 4E), while 3αHP resulted in suppression (Figure 4F) of gelatinase expression.

Effects of 5αP and 3αHP on expression of TIMPs

Since TIMPs inhibit the enzymatic activity of MMPs, a decrease in TIMP expression can lead to increased MMP activity and vice versa. Results from experiments to determine the effects of 5αP and 3αHP on MDA-MB-231 cell expression of TIMP-1 and TIMP-2 are shown in Figure 5. 5αP suppressed (Figures 5A & 5C), whereas 3αHP stimulated (Figures 5B &5D) expression of TIMP-1 and TIMP-2.

Previous studies showed that proliferation of TNBC cells in vitro [14], and initiation and growth of primary TNBC tumors in vivo [15] are stimulated by 5αP and inhibited by 3αHP. The opposing effects on TNBC cell proliferation result from opposing actions of 5αP and 3αHP on breast cell mitosis and apoptosis [14]. The findings described here show for the first time that 5αP stimulates, whereas 3αHP suppresses, TNBC cell detachment, migration and invasion, the cardinal processes involved in cancer cell metastasis. In addition, the studies show that these opposing effects are directly correlated with the opposing effects of 5αP and 3αHP on expression and activation of MMPs, which regulate adhesion properties between cells and between cells and ECM, and thereby control the changes in migration and invasion. Corroborating our findings are results from other studies which have shown that up-regulation of MMPs facilitates increased migration and invasion [23, 29- 31], whereas down-regulation of MMPs by anti-cancer and/or anti-metastatic agents inhibits cell migration and invasion [24,32,33].

The relevance of the findings that 5αP stimulates and 3αHP inhibits the deregulation of TNBC cells from a state of normalcy to one of tumorigenesis and metastasis, is enhanced by observations that TNBC tissues [9] and tumorigenic cells [14] convert more progesterone to 5αP, and less to 3αHP, than normal tissue and nontumorigenic breast cells, as a result of higher expression of 5α-reductase (SRD5A1; SRD5A2) and lower expression of 3α-HSO (AKR1C2; AKR1C3) genes [10; 11]. The resulting increases in 5αP:3αHP concentration ratios in the breast microenvironment correlate with the observed increases in TNBC cell mitogenic and metastatic activities [9, 15].

Molecular mechanisms of action of 5αP and 3αHP

The opposing actions of 5αP and 3αHP can be explained, in part, by studies which have identified separate receptors for 5αP (5αPR) and 3αHP (3αHPR) and their interactions with cell signalling cascades. The 5αPR and 3αHPR are located on plasma membranes of breast cells [34]. They exhibit high specificity and are distinct from each other and from known receptors of other steroid hormones [34,35 ]. Binding of 5αP to its receptor results in activation of MAPK/ERC [35] which is known to upregulate MMP expression/activity [36,37] leading to decreases in adhesion plaques, vinculin expression and polymerized actin [38] and promoting increased detachment, migration and invasion [39-40]. On the other hand, 3αHP can inhibit protein kinase C (PKC) activity ([41], and unpublished results) which, in turn, can lead to suppression of MMP activation, and the resulting inhibition of cell invasion and migration [42, 43].

Based on previous and current findings we propose the following model (Fig. 6) to explain how 3αHP and 5αP, can regulate the adhesive, migratory, and invasive processes integral to metastasis of triple- negative breast cancers. 3αHP and 5αP, derived from autocrine and/or paracrine sources, couple with their respective plasma membrane-based receptors, triggering suppression or activation, respectively of PKC or MAPK signaling pathways. Binding of 5αP to its receptor activates the MAPK/ERK1/2 signaling cascade resulting in increased expression of MMPs and/or decreased expression of TIMPs, leading to stimulation of proteolytic degradation of the ECM and providing enhanced ability of cells to detach, migrate and invade. Binding of 3αHP to its receptor results in down regulation of PKC activity which leads to decreased expression of MMPs-2/9 and/or increased expression of TIMPs-1/2, resulting in decreased proteolytic degradation of the surrounding ECM, thereby suppressing cell detachment, migration, and invasion. The relative concentrations of 3αHP and 5αP in the microenvironment determine whether local clusters of breast cells maintain a state of "normalcy" or proceed toward metastasis. A higher 3αHP-to-5αP concentration ratio promotes normalcy, whereas a higher 5αP-to-3αHP concentration ratio promotes mitogenesis and metastasis of TNBC. The findings suggest (a) that tests which measure the relative concentrations of 5αP:3αHP in a patient's blood, saliva or tissue samples could serve as prognostics/diagnostics for the status of a TNBC patient, and (b) that blocking synthesis of 5αP and increasing 3αHP concentrations in the breast microenvironment can provide a hormone-based therapeutic measure to block TNBC onset, progression and metastasis.

TNBC: triple-negative breast cancer; ER: estrogen receptor; PR: progesterone receptor; 5alphaP: 5alpha-pregnane-3,20-dione (5alpha-dihydroprogesterone); 3alphaHP: 4-pregnen-3alpha-ol-20-one (3alpha-dihydroprogesterone); MAPK: mitogen-activated protein kinase; PKC: protein kinase C; MMP: matrix metalloproteinase; TIMP:tissue inhibitor of metalloproteinase

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analysed during the current study

Competing interests

The authors declare that they have no competing interests.

Funding

The research was supported by a grant from the Canadian Institutes of Health Research and Canadian Breast Cancer Research Alliance to JPW.

Author's contributions

JPW conceived the study, created the study design, performed data analyses, assisted in preparation of the figures and drafted the manuscript. JJ assisted in the study design, performed the migration and invasion studies, data analyses and assisted in manuscript editing. AK performed the MMP and TIMP expression studies and assisted in data analyses and manuscript preparation.

Acknowledgements

Technical assistance was provided by Biljana Popovic, and Emily Sodhi assisted in manuscript editing.

Author details

John P. Wiebe* (correspondence), Department of Biology, Western University, Biological & Geological Sciences Building, 1151 Richmond Street N., London, Ontario, Canada N6A5B7.

(email: [email protected]; PH: 519-661-2111 Ext.83131)

Jordan Jarvis, London School of Hygiene and Tropical Medicine, Keppel St., Bloomsbury, London WC1E7HT, United Kingdom ([email protected])

Arthur Kwok, Department of Biology, Western University, London, Ontario N6A5B7, Canada

[1] American Cancer Society: Global Cancer Facts & Figures. 4th edition. Atlanta,

American Cancer Society; 2018 [https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf].

[2] Breastcancer.org: Triple-negative breast cancers, http://www.breastcancer.org (2019).

[3] Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007, 109:1721–1728.

[4] Hudis CA, Gianni L: Triple-negative breast cancer: An unmet medical need.Oncologist 2011, 16:1–11.

[5] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429–4434

[6] Dawood S, Broglio K, Esteva FJ, Yang W, Kau S-W, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009, 20:621–627.

[7] Gadi VK, Davidson NE: Practical approach to triple-negative cancer. J Oncol Pract 2017, 13:293–300.

[8] Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S: Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.Asia Pac J Clin Oncol 2018, 14:32–39.

[9] Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL: The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000, 60:936–943.

10] Wiebe JP, Lewis MJ: Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 2003, 3:9.

[11] Lewis MJ, Wiebe JP, Heathcote JG: Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004, 4:27.

[12] Li T, Zhang W, Lin S-X. Steroid enzyme and receptor expression and regulation in breast tumor samples – A statistical evaluation of public data. J Steroid Biochem Mol Biol 2020, 196, ttps:doi.org/10.1016/j.jsbmb.2019. 105494.

[13] Chavez KJ, Garimella SV, Lipkowitz S. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for better treatment of Triple Negative Breast Cancer. Breast Disease 2010, 32, 35 - 48. doi:10,3233/BD-20100307.

[14] Wiebe JP, Beausoleil M, Zhang G, Cialacu V: Opposing actions of the progesterone metabolites, 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol 2010, 118:125–132.

[15] Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HT: Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Res 2013, 15:R38.

http://breast-cancer-research.com/content/15/3/R38

[16 ] Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 1997, 80:1529-37

]17] Bonnans C, Chou J, Werb Z: Remodelling the extracellular matrix in development and disease. Nature Reviews. Molecular Cell Biology. 2014,15 : 786–801. doi:10.1038/nrm3904. PMC 4316204. PMID 25415508.

[18] Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52–67.

[19] Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000, 10:415–433.

[20] Fingleton B: Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006, 11:479–491.

21] Bode W, Fernandez-Catalan C, Grams F, Gomis-Rüth FX, Nagase H, Tschesche H, Maskos K: Insights into MMP-TIMP interactions. Ann N Y Acad Sci 1999, 878:73–91.

[22] Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477: 267–283.

[23] Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH, Jeong HG: Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett 2011, 585:421–428.

[24] Lee MM, Chen YY, Liu PY, Hsu S, Sheu MJ: Pipoxolan inhibits CL1-5 lung cancer cells

migration and invasion through inhibition of MMP-9 and MMP-2. Chem Biol Interact 2015, 236: 19–30.

[25] Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M, Matache C: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006, 10: 499–510.

[26] Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells.Cancer Res 1987, 47:3239–3245.

[27] Albini A, Benelli R: The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation.Nat Protoc 2007, 2:504–511.

[28] Grant DS, Kleinman HK, Leblond CP, Inoue S, Chung AE, Martin GR: The basement-membrane-like matrix of the mouse EHS tumor: II. Immunohistochemical quantitation of six of its components. Am J Anat 1985, 174:387–398.

[29] Hegedüs L, Cho H, Xie X, Eliceiri GL: Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 2008, 216:480–485.

[30] Kim IY, Yong HY, Kang KW, Moon A: Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett 2009, 275: 227–233.

[31] Park S, Kim ES, Noh DY, Hwang KT, Moon A: H-Ras-specific upregulation of granulocyte colony-stimulating factor promotes human breast cell invasion via matrix metalloproteinase-2. Cytokine 2011, 55:126–133.

[32] Li L, Chen P, Ling Y, Song X, Lu Z, He Q, Li Z, Lu N, Guo Q: Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Eur J Pharm Sci 2011, 43:393–399.

[33] Chen P, Lu N, Ling Y, Chen Y, Hui H, Lu Z, Song X, Li Z, You Q, Guo Q: Inhibitory effects of wogonin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. Toxicology 2011, 282:122–128.

[34] Weiler PJ, Wiebe JP: Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5α-pregnane-3,20-dione and 3α-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2000, 272:731–737.

[35] Wiebe JP, Pawlak KJ, Kwok A: Mechanism of action of the breast cancer-promoter hormone, 5α-dihydroprogesterone (5αP), involves plasma membrane-associated receptors and MAPK activation.J Steroid Biochem Mol Biol 2016, 155:166–176.

[36] Reddy KB, Krueger JS, Kondapaka SB, Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999, 82: 268–273.

[37] Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC: TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012, 12:26.

[38] Wiebe JP, Muzia D: The endogenous progesterone metabolite, 5α-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells. Endocrine 2001, 16:7–14.

[39]Liu Y, Zhu P, Wang Y, Wei Z, Tao L, Zhu Z, Sheng X, Wang S, Ruan J, Liu Z, Cao Y, Shan Y, Sun L, Wang A, Chen W, Lu Y: Antimetastatic therapies of the polysulfide diallyl trisulfide against triple-negative breast cancer (TNBC) via suppressing MMP2/9 by blocking NF-κB and ERK/MAPK signaling pathways. PLoS One 2015, 10:e0123781.

[40] Zhang Y, Liu J, Kou J, Yu J, Yu B: DT-13 suppresses MDA-MB-435 cell adhesion and invasion by inhibiting MMP-2/9 via the p38 MAPK pathway. Mol Med Rep 2012, 6:1121–5.

[41] Wiebe JP. Nongenomic actions of steroids on gonadotropin release. Recent Prog Horm Res 1997, 52:71–101

[42] Karroum A, Mirshahi P, Benabbou N, Faussat AM, Soria J, Therwath A, Mirshahi M, Hatmi M: Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways. Cancer Lett 2010, 295:242–251.

[43] Noh EM, Park, YJ, Kim JM, Kim MS, Kim HR, Song HK, Hong OY, So HS, Yang SH, Kim JS, Park SH, Youn HJ, You YO, Choi KB, Kwon KB, Lee YR: Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J Pharmacol 2015, 764:79–86.

Download PDF

Version 1

posted

You are reading this latest preprint version

Triple-Negative Breast Cancer (TNBC) Cell Metastasis is Controlled by the Opposing Actions of 5alpha-dihydroprogesterone (5alphap) and 3alpha-dihydroprogesterone (3alphahp) on Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases

Status:

Version 1

Abstract

Figures

Background

Methods And Materials

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Status:

Version 1